Company intelligence / Profile preview
Xcyte Therapies
Seattle, Washington, USAxcytetherapies.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Xcyte Therapies developed ex vivo cellular therapies using its proprietary Xcellerate Technology to activate and expand autologous T cells for treating cancer, infectious diseases, and immunodeficiencies. The company’s lead programs were discontinued after regulatory setbacks. Its core technology was sold to Invitrogen in 2005 for $5 million. The remaining business merged with Cyclacel Pharmaceuticals via a reverse merger in late 2005, ceasing independent operations.
- Therapeutic areas
- Infectious DiseasesDermatologyImmunologyOncology
- Modalities
- Cell therapyActivated T cells
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Genetics Institute/BioPharma licensing agreements for ex vivo activation/expansion patents.Technology sale to Invitrogen.
Beyond the preview
Go deeper on Xcyte Therapies.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Xcyte Therapies.